Nkarta - Model NKG2D - NKX101 - Activating Receptor
From Pipeline
OX40 costimulatory domain, CD3ζ signaling moiety, membrane bound IL-15.
-
Most popular related searches
Engineered to Target Nkg2d Ligands
- Opportunity to treat a variety of hematologic malignancies and solid tumors
- Targets of NKG2D are selectively over-expressed in cancer cells
- Native NK activation and tumor killing largely driven by NKG2D receptor
- For NKX101, expression of the activating chimeric receptor is increased 10X relative to nonengineered NK cells
- OX40 selected based on superiority vs. other costimulatory domains
- A Phase 1 clinical trial of NKX101 is currently enrolling patients.
Customer reviews
No reviews were found for Nkarta - Model NKG2D - NKX101 - Activating Receptor. Be the first to review!